Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.

ABSTRACT: Androgens play a critical role in the progression of castration-resistant prostate cancer through androgen receptor (AR)-regulated signaling pathways. Progress has been made in the development of potent agents designed to suppress androgen function by blocking the AR, inhibiting the synthesis of androgens, or targeting downstream AR signaling pathways. This review summarizes the development of novel therapies based on current insights into AR signaling pathways in castration-resistant prostate cancer.

SUBMITTER: Zhu W 

PROVIDER: S-EPMC6357221 | biostudies-other | 2010 Mar-Apr

REPOSITORIES: biostudies-other